Botta, Cirino
 Distribuzione geografica
Continente #
NA - Nord America 1390
EU - Europa 399
AS - Asia 45
SA - Sud America 10
AF - Africa 5
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 1857
Nazione #
US - Stati Uniti d'America 1378
IT - Italia 237
RU - Federazione Russa 40
DE - Germania 19
GB - Regno Unito 18
EE - Estonia 16
CN - Cina 12
UA - Ucraina 12
CA - Canada 11
CH - Svizzera 10
FR - Francia 8
HK - Hong Kong 8
BE - Belgio 6
IN - India 5
NL - Olanda 5
SE - Svezia 5
UZ - Uzbekistan 5
JP - Giappone 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AR - Argentina 3
AT - Austria 3
BR - Brasile 3
CL - Cile 3
CZ - Repubblica Ceca 3
GR - Grecia 3
IE - Irlanda 3
NZ - Nuova Zelanda 3
AU - Australia 2
EG - Egitto 2
KR - Corea 2
LK - Sri Lanka 2
NO - Norvegia 2
RO - Romania 2
RS - Serbia 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
DK - Danimarca 1
ES - Italia 1
FI - Finlandia 1
HU - Ungheria 1
LB - Libano 1
MA - Marocco 1
MO - Macao, regione amministrativa speciale della Cina 1
MX - Messico 1
PE - Perù 1
SG - Singapore 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
TR - Turchia 1
ZA - Sudafrica 1
Totale 1857
Città #
Fairfield 276
Chandler 231
Medford 122
Wilmington 117
Altamura 115
Princeton 79
Lawrence 77
Cambridge 75
Ashburn 73
San Diego 64
Houston 62
Woodbridge 45
Seattle 33
Ann Arbor 30
Tallinn 16
Saint Petersburg 11
San Paolo di Civitate 9
Toronto 8
Florence 7
Palermo 7
Brussels 6
Beijing 5
Central District 5
Chicago 5
London 5
Milan 5
Norwalk 5
Redwood City 5
Bremen 4
Catanzaro 4
Clearwater 4
Moscow 4
Apo 3
Auckland 3
Kiev 3
Ponzano Veneto 3
Rome 3
Shanghai 3
São Paulo 3
Tokyo 3
Amsterdam 2
Andover 2
Bari 2
Beograd 2
Cairo 2
Castrovillari 2
Catania 2
Cedar Knolls 2
Central 2
Colombo 2
Den Haag 2
Gossolengo 2
Grimaldi 2
Heidelberg 2
Karlsruhe 2
Kingswinford 2
Lloydminster 2
Melbourne 2
Mountain View 2
Mumbai 2
Naples 2
New York 2
Oslo 2
San Francisco 2
Suri 2
Turin 2
Vienna 2
Aurora 1
Bagnara di Romagna 1
Bensalem 1
Boston 1
Bratislava 1
Breda 1
Brescia 1
Budapest 1
Büdelsdorf 1
Campofranco 1
Cassano Allo Ionio 1
Centurion 1
Cernobbio 1
Council Bluffs 1
Cupertino 1
Dallas 1
Darmstadt 1
Delhi 1
Dubai 1
Duncan 1
Eden Prairie 1
Falkenstein 1
Federal 1
Genoa 1
Genova 1
Guangzhou 1
Hanoi 1
Harbin 1
Helsinki 1
Ilsan 1
Kemerovo 1
La Canada Flintridge 1
La Jolla 1
Totale 1625
Nome #
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation 99
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 62
Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing 47
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients 46
Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev) 45
Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report 38
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: Do we still need it? 38
Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility 37
The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis 37
Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report 37
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients 36
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma 35
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 35
Pharmacokinetics and pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and non-human primates 35
OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes 35
Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma 34
Mouse models of multiple myeloma: Technologic platforms and perspectives 34
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials 34
COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm 33
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 33
Tumor infiltration by chemokine receptor 7 (CCR7)+ T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer 32
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 32
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 32
Iron Metabolism in the Tumor Microenvironment-Implications for Anti-Cancer Immune Response 32
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 31
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma 31
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 31
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 30
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 30
miR-22 suppresses DNA ligase III addiction in multiple myeloma 30
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 30
Mechanisms of immune evasion in multiple myeloma: Open questions and therapeutic opportunities 30
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology 30
Immunologic characterization of COVID-19 patients with hematological cancer 29
Myeloid derived suppressor cells in multiple myeloma: Preclinical research and translational opportunities 29
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients 29
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma 29
Could PD-1/PDL1 immune checkpoints be linked to HLA signature? 29
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma 28
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients 28
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients 28
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 28
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 27
Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro 27
The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response 27
A p53-Dependent Tumor Suppressor Network Is Induced by Selective miR-125a-5p Inhibition in Multiple Myeloma Cells 27
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: Italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 27
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma 26
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 26
Immunotherapy of colorectal cancer: New perspectives after a long path 26
Systemic inlammatory status at baseline predicts bevacizumab beneit in advanced non-small cell lung cancer patients 25
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 25
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine 25
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients 25
Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer 24
A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells 24
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 24
The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells 24
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies 24
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 24
Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab 23
Immunomodulatory activity of microRNAs: Potential implications for multiple myeloma treatment 23
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 23
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse 23
MIR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 23
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 23
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease 23
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials 23
Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation 22
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients 22
A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma 22
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in relapsed/refractory patients 21
Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice 21
Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials 20
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 20
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination 19
Elotuzumab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 18
Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma 17
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma 17
Network meta-analysis of randomized trials in multiple myeloma efficacy and safety in frontline therapy for patients not eligible for transplant 16
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy 13
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach 12
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 3
Totale 2392
Categoria #
all - tutte 5918
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5918

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021774 0000 00 00 9419742
2021/2022913 561312828 2376 4442 10015461170
2022/2023705 10924994113 1400 00 0000
Totale 2392